Abbvie (ABBV) closed at $291.31 on November 6, 2026, up 1.1% from the previous close, on volume of 4,169,009 shares (30-day average 5,318,510).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Put Spread | 20-Nov-26275 : 285 P | 5,000 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
AbbVie Advances New Facial-Line Injection Study as Investors Watch Aesthetic Growth
TipRanks (Thu, 5-Nov 11:32 AM ET)
AbbVie Updates Early-Stage Drug Interaction Study: What ABBV Investors Should Know
TipRanks (Thu, 5-Nov 11:31 AM ET)
AbbVie, Nxera ink licensing deal worth up to $1.5B for bowel disease therapy
Seeking Alpha News (Wed, 4-Nov 1:22 PM ET)
Most and least shorted mid- to mega-cap healthcare stocks at the end of October
Seeking Alpha News (Tue, 3-Nov 10:00 AM ET)
PRNewswire (Tue, 3-Nov 8:00 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV)
TipRanks (Tue, 3-Nov 5:10 AM ET)
PRNewswire (Mon, 2-Nov 9:00 AM ET)
AbbVie Reports Third-Quarter 2026 Financial Results
PRNewswire (Fri, 30-Oct 7:46 AM ET)
PRNewswire (Thu, 29-Oct 6:01 AM ET)
The Countdown Is On: BOTOX Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
PRNewswire (Wed, 28-Oct 8:01 AM ET)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
Abbvie trades on the NYSE stock market under the symbol ABBV.
As of November 6, 2026, ABBV stock price climbed to $291.31 with 4,169,009 million shares trading.
ABBV has a beta of -0.62, meaning it tends to be less sensitive to market movements. ABBV has a correlation of 0.08 to the broad based SPY ETF.
ABBV has a market cap of $515.26 billion. This is considered a Mega Cap stock.
Last quarter Abbvie reported $17 billion in Revenue and $3.82 earnings per share. This beat revenue expectation by $53 million and exceeded earnings estimates by $.05.
In the last 3 years, ABBV traded as high as $302.93 and as low as $135.85.
The top ETF exchange traded funds that ABBV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ABBV has outperformed the market in the last year with a price return of +36.2% while the SPY ETF gained +10.8%. ABBV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +20.2% and +2.0%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
ABBV support price is $282.96 and resistance is $293.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABBV shares will trade within this expected range on the day.
